JAGX Nasdaq· Jaguar Health Inc.
FundamentalsNews digest Peer analysis
JAGX Nasdaq· Jaguar Health Inc.
Earnings report Q3 2023

Jaguar Health Reports Decline in Product Revenue for the Latest Quarter

Segments of revenue

In the latest quarter, Jaguar Health reported product revenue of $2.81 million, a decrease from $3.15 million in the same quarter last year. For the nine months ended September 30, 2023, product revenue amounted to $7.46 million, down from $8.70 million in the prior year period.


Despite the decline in product revenue, Jaguar Health remains focused on developing novel, plant-based prescription medicines for gastrointestinal distress. The company's subsidiary, Napo Pharmaceuticals, continues to drive the development of these medicines, which could provide future revenue growth opportunities.


The decrease in product revenue indicates a challenge for Jaguar Health in generating consistent sales. The company may need to evaluate its sales and marketing strategies to improve product uptake and increase revenue.


It is worth noting that Jaguar Health recorded a gain of $3.70 million on the extinguishment of debt during the quarter. This gain helped offset the loss from operations and contributed to a narrower net loss for the period.


Jaguar Health experienced a decline in product revenue for the latest quarter, reflecting a challenge in generating consistent sales. However, the company's focus on developing novel prescription medicines and the gain on extinguishment of debt provide some strengths and opportunities for future growth. Jaguar Health should continue to evaluate its sales and marketing strategies to improve revenue performance.

Source documents

Form 10-Q  filed on Nov 14, 2023
47 pages scanned

Reference data

Company financials Q3 revenue 2.3M
Analyst estimates Q3 EPS missed by -100.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.